tiprankstipranks
Trending News
More News >
Portage Biotech (PRTG)
:PRTG
US Market

Portage Biotech Inc (PRTG) Price & Analysis

Compare
123 Followers

PRTG Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

<0.01%1.72%98.27%
Insiders
1.72% Other Institutional Investors
98.27% Public Companies and Individual Investors

PRTG FAQ

What was Portage Biotech’s price range in the past 12 months?
Portage Biotech lowest stock price was $2.09 and its highest was $23.01 in the past 12 months.
    What is Portage Biotech’s market cap?
    Portage Biotech’s market cap is $12.90M.
      When is Portage Biotech’s upcoming earnings report date?
      Portage Biotech’s upcoming earnings report date is Aug 13, 2025 which is in 36 days.
        How were Portage Biotech’s earnings last quarter?
        Currently, no data Available
        Is Portage Biotech overvalued?
        According to Wall Street analysts Portage Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Portage Biotech pay dividends?
          Portage Biotech pays a Notavailable dividend of $948 which represents an annual dividend yield of N/A. See more information on Portage Biotech dividends here
            What is Portage Biotech’s EPS estimate?
            Portage Biotech’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Portage Biotech have?
            Portage Biotech has 2,278,622 shares outstanding.
              What happened to Portage Biotech’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Portage Biotech?
              Currently, no hedge funds are holding shares in PRTG

              Company Description

              Portage Biotech

              Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
              Similar Stocks
              Company
              Price & Change
              Follow
              EKSO BIONICS
              Biomerica
              ABVC BioPharma
              Addex Therapeutics
              Addex Therapeutics
              Dogwood Therapeutics
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis